AbbVie (NYSE: ABBV) COO receives options and performance-based shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
AbbVie Inc. executive vice president and chief operations officer Azita Saleki-Gerhardt reported equity compensation grants. She received an employee stock option for 20,312 shares at a grant price of $0.00, vesting in three annual installments of 6,771, 6,771 and 6,770 shares on February 18, 2027, February 18, 2028, and February 18, 2029.
She also acquired multiple blocks of AbbVie common stock through performance-based share and restricted stock unit awards, with grants from February 16, 2023, February 15, 2024, and February 13, 2025 tied to earnings per share, relative total shareholder return, and relative return on equity. These performance-vesting restrictions were certified as attained on February 18, 2026, and the shares will be issued on February 28, 2026. Additional indirect holdings include shares in an AbbVie savings program and shares held by her spouse, for which she disclaims beneficial ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
7 transactions reported
Mixed
7 txns
Insider
SALEKI-GERHARDT AZITA
Role
EVP, CHIEF OPERATIONS OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option (Right to Buy) | 20,312 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 17,041 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 6,058 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 7,074 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 6,638 | $0.00 | -- |
| holding | Common Stock, $0.01 par value | -- | -- | -- |
| holding | Common Stock, $0.01 par value | -- | -- | -- |
Holdings After Transaction:
Option (Right to Buy) — 20,312 shares (Direct);
Common Stock, $0.01 par value — 194,333 shares (Direct);
Common Stock, $0.01 par value — 2,706 shares (Indirect, Profit sharing trust)
Footnotes (1)
- Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Balance in AbbVie Savings program as of February 20, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature. The reporting person disclaims beneficial ownership of all securities held by her spouse. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,771 on February 18, 2027, 6,771 on February 18, 2028, and 6,770 on February 18, 2029.
FAQ
What insider transactions did AbbVie (ABBV) report for Azita Saleki-Gerhardt?
AbbVie reported equity compensation grants to EVP and COO Azita Saleki-Gerhardt, including a 20,312-share employee stock option and several performance-based stock awards. These awards reflect long-term incentive compensation rather than open-market share purchases or sales.
How many AbbVie (ABBV) options were granted to Azita Saleki-Gerhardt in this Form 4?
Azita Saleki-Gerhardt received an employee stock option covering 20,312 AbbVie shares at a grant price of $0.00. The option was issued under AbbVie’s Amended and Restated 2013 Incentive Stock Program as part of her executive compensation package.
What is the vesting schedule of the new AbbVie (ABBV) stock options?
The 20,312-share stock option vests in three annual installments: 6,771 shares on February 18, 2027, 6,771 shares on February 18, 2028, and 6,770 shares on February 18, 2029. Vesting is time-based under AbbVie’s incentive stock program.
What performance conditions apply to the AbbVie (ABBV) stock awards in this filing?
The reported common stock awards are subject to performance-vesting conditions based on earnings per share, relative total shareholder return, and relative return on equity. Vesting occurred after AbbVie’s Compensation Committee certified achievement of these performance goals on February 18, 2026.
How are indirect AbbVie (ABBV) holdings treated in this Form 4 filing?
Indirect holdings include shares in an AbbVie savings program and shares held by Azita Saleki-Gerhardt’s spouse. The filing notes she disclaims beneficial ownership of all securities held by her spouse, clarifying these shares are not treated as her direct beneficial holdings.